2025;74(Supplement 1):1966-LB
Restlessness and anxiety can emerge, particularly in the first week as the body adjusts to heightened norepinephrine activity
Our customized medical weight loss programs offer a structured, physician-supervised approach tailored specifically to your unique health profile, lifestyle, and personal aesthetic goals, ensuring safe, effective, and sustainable results
Regulatory Approvals/Commercial Semaglutide is a GLP-1 analog, developed in 2012 by Novo Nordisk, as a longer acting alternative to liraglutide
Generally, research suggests that injectable semaglutide achieves significantly greater HbA1c reductions compared to oral forms in those with type 2 diabetes
These tend to subside as your body acclimates to the medication